Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Woodline Partners LP

Key Points

• Woodline Partners LP reduced its stake in Arrowhead Pharmaceuticals by 33.1%, holding 562,175 shares worth approximately $7.16 million after selling 277,999 shares in the first quarter.
• Insider James C. Hamilton sold 15,000 shares of Arrowhead stock for $375,000, resulting in a decreased ownership of 5.72% and leaving him with 247,122 shares valued at around $6.18 million.
• Arrowhead Pharmaceuticals reported a quarterly loss of ($1.26) earnings per share (EPS), missing the expectations, with a revenue of $27.77 million compared to anticipated revenue of $29.01 million.

Woodline Partners LP cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 33.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 562,175 shares of the biotechnology company's stock after selling 277,999 shares during the quarter. Woodline Partners LP owned 0.41% of Arrowhead Pharmaceuticals worth $7,162,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at $49,000. CWM LLC boosted its stake in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 2,523 shares during the last quarter. Mackenzie Financial Corp bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at $137,000. Finally, KBC Group NV boosted its stake in Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 2,132 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock traded up $1.85 during trading hours on Thursday, reaching $30.98. The stock had a trading volume of 844,306 shares, compared to its average volume of 2,039,405. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $31.14. The firm has a 50-day simple moving average of $20.67 and a 200-day simple moving average of $16.76. The firm has a market capitalization of $4.28 billion, a PE ratio of -24.19 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the business posted ($1.38) earnings per share. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the sale, the insider owned 232,122 shares of the company's stock, valued at $6,963,660. This trade represents a 6.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 40,000 shares of company stock valued at $1,025,000. 4.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Finally, Royal Bank Of Canada reduced their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of "Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.